AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9093728 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 407
Study 2202553 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% percutaneous niflumic acid gel applied 3-times daily for 7 days
Number of subjects: 60
Study 2202553 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied 3-times daily for 7 days
Number of subjects: 60
Study 6786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone Enanthate (NEN)
Number of subjects: 20
Study 6786825 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone Acetate (NET)
Number of subjects: 20
Study 30850868 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome guidance at 110 beats/min (test 2)
Number of subjects: 36
Study 30850868 — intervention group
Group type: COMPARATOR
Intervention: No metronome guidance (baseline test/test 1)
Number of subjects: 36
Study 27837524 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week aerobic exercise (moderate volume group)
Number of subjects: 400
Study 27837524 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 min/week aerobic exercise (high volume group)
Number of subjects: 400
Study 27837524 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volume of aerobic exercise
Number of subjects: 400
Study 27837524 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status as a moderator
Number of subjects: 400
Study 27837524 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity as a moderator
Number of subjects: 400
Study 26450209 — intervention group
Group type: EXPERIMENTAL
Intervention: Math story time with parents using an iPad app
Number of subjects: 587
Study 26450209 — intervention group
Group type: COMPARATOR
Intervention: Reading (control group)
Number of subjects: 587
Study 23770110 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training sessions with individualized action plans for COPD and comorbidities, linked to daily symptom diaries for 12 months.
Number of subjects: 300
Study 23770110 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care with COPD action plans).
Number of subjects: 300
Study 21917304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin oral controlled absorption system 0.4 mg/d for 1 month
Number of subjects: 248
Study 21917304 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (corticosteroids and analgesics)
Number of subjects: 248
Study 18215978 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV+IDV
Number of subjects: 283
Study 18215978 — intervention group
Group type: COMPARATOR
Intervention: EFV+IDV plus ABC
Number of subjects: 283
Study 17003662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 7
Study 14637325 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressuring strategies
Number of subjects: 0
Study 14637325 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling and looking good strategies
Number of subjects: 0
Study 10913922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture group (31 women)
Number of subjects: 53
Study 10913922 — intervention group
Group type: COMPARATOR
Intervention: Nonfracture group (22 women)
Number of subjects: 53
Study 10913922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture group (men)
Number of subjects: 53
Study 10913922 — intervention group
Group type: COMPARATOR
Intervention: Nonfracture group (men)
Number of subjects: 53
Study 8908377 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study 8908377 — intervention group
Group type: COMPARATOR
Intervention: DNA-recombinant insulin
Number of subjects: 60
Study 1929843 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) evaluation in 31 patients
Number of subjects: 85
Study 1929843 — intervention group
Group type: COMPARATOR
Intervention: Conventional evaluation in 30 patients
Number of subjects: 85
Study 6126126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 7
Study 6126126 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 7
Study 31915175 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integration of palliative care (EIPC) on a monthly basis
Number of subjects: 214
Study 31915175 — intervention group
Group type: COMPARATOR
Intervention: Optimised standard care (control group)
Number of subjects: 214
Study 31915175 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integration of palliative care (EIPC)
Number of subjects: 214
Study 30828820 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of accurate information about the proportion of whole blood donors who experience faint and prefaint reactions
Number of subjects: 3702
Study 30828820 — intervention group
Group type: COMPARATOR
Intervention: Control group (no accurate information provided)
Number of subjects: 3702
Study 28943117 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% benzocaine alone
Number of subjects: 40
Study 28943117 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% benzocaine plus 2% tetracaine
Number of subjects: 40
Study 28943117 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mL of 14% benzocaine plus 0.2% benzocaine
Number of subjects: 40
Study 24720763 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 0.3 before removal of the LMA
Number of subjects: 60
Study 24720763 — intervention group
Group type: COMPARATOR
Intervention: FIO2 1.0 before removal of the LMA
Number of subjects: 60
Study 24720763 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis
Number of subjects: 60
Study 21555333 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean breath alcohol concentration = 68 mg/dL)
Number of subjects: 30
Study 21555333 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control (0 mg/dL)
Number of subjects: 30
Study 19440173 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane dressing
Number of subjects: 60
Study 19440173 — intervention group
Group type: COMPARATOR
Intervention: Silicone sheet
Number of subjects: 60
Study 17894701 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream (1%)
Number of subjects: 40
Study 17894701 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study 15193942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid sequences
Number of subjects: 12
Study 15193942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous sequences
Number of subjects: 12
Study 11533310 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0
Study 9504867 — intervention group
Group type: EXPERIMENTAL
Intervention: 13N-ammonia PET
Number of subjects: 31
Study 9504867 — intervention group
Group type: COMPARATOR
Intervention: 99mTc-sestamibi SPECT
Number of subjects: 31
Study 8137435 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐A,‐B and HLA‐DR antigen matching
Number of subjects: 456
Study 8137435 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive crossmatch donor
Number of subjects: 456
Study 8137435 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-compatible group
Number of subjects: 456
Study 8137435 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-incompatible group
Number of subjects: 456
Study 2701744 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 58
Study 2701744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27854116 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% orange juice with vitamin C 70 mg daily (G2)
Number of subjects: 60
Study 27854116 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 60
Study 31766987 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based sexual assault prevention program (IMPower and Sources of Strength)
Number of subjects: 0
Study 31766987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31239304 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol inhaled with gas flow of 50 L/min
Number of subjects: 0
Study 31239304 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol inhaled with GF:IF=1.0
Number of subjects: 0
Study 31239304 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol inhaled with GF:IF=0.5
Number of subjects: 0
Study 31239304 — intervention group
Group type: COMPARATOR
Intervention: 2 mL saline inhaled before albuterol doses
Number of subjects: 0
Study 28285649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO) treatment for 12 weeks
Number of subjects: 24
Study 28285649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 24
Study 25956370 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) and hMG administered simultaneously
Number of subjects: 300
Study 25956370 — intervention group
Group type: COMPARATOR
Intervention: Short protocol (control group)
Number of subjects: 300
Study 23942523 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personally controlled health management system (PCHMS) called Healthy.me
Number of subjects: 300
Study 23942523 — intervention group
Group type: COMPARATOR
Intervention: Information websites (usual care arm)
Number of subjects: 300
Study 21155616 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg
Number of subjects: 120
Study 21155616 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg/Lisinopril 10 mg
Number of subjects: 120
Study 21155616 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 120
Study 21155616 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 120
Study 19221241 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrasted test (modified distractors)
Number of subjects: 30
Study 19221241 — intervention group
Group type: COMPARATOR
Intervention: Classic test (standard distractors)
Number of subjects: 30
Study 16847409 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt weaning
Number of subjects: 222
Study 16847409 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding (control)
Number of subjects: 222
Study 12490768 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 40
Study 12490768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10792142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microgram.kg‐1 intravenous fentanyl
Number of subjects: 60
Study 10792142 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 10792142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 60
Study 10792142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9497468 — intervention group
Group type: COMPARATOR
Intervention: Gas tamponade alone (20% SF6)
Number of subjects: 85
Study 9497468 — intervention group
Group type: COMPARATOR
Intervention: Gas tamponade with TGF-beta 2 (20% SF6 gas + TGF-beta 2)
Number of subjects: 85
Study 9497468 — intervention group
Group type: COMPARATOR
Intervention: Gas tamponade with autologous platelet concentrate (16% C3F8 gas + 0.1 ml autologous platelet concentrate)
Number of subjects: 85
Study 7686981 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide (luteinizing hormone-releasing hormone agonist) given as an injection every 28 days for 24 weeks
Number of subjects: 50
Study 7686981 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide (luteinizing hormone-releasing hormone agonist)
Number of subjects: 50
Study 7686981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3092689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (SCG)
Number of subjects: 54
Study 3092689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29991458 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 200
Study 29991458 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV
Number of subjects: 200
Study 29991458 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 27814472 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 μg once a day)
Number of subjects: 292
Study 27814472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 25480461 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 289
Study 25480461 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-mailed intervention
Number of subjects: 289
Study 25480461 — intervention group
Group type: COMPARATOR
Intervention: Standard advice
Number of subjects: 289
Study 23390825 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40
Study 23390825 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 20846063 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with professional patients
Number of subjects: 87
Study 20846063 — intervention group
Group type: COMPARATOR
Intervention: Training with clinical patients
Number of subjects: 87
Study 17570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine 30 mg/m² for 6 days and oral busulfan 4 mg/kg/day for 2 days
Number of subjects: 30
Study 17570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and busulfan regimen
Number of subjects: 30
Study 16088264 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Therapy (BT)
Number of subjects: 31
Study 16088264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FLV)
Number of subjects: 31
Study 16088264 — intervention group
Group type: COMPARATOR
Intervention: Control group (autogenic training +/− pill placebo)
Number of subjects: 31
Study 12187208 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly leuprolide acetate (7.5 mg)
Number of subjects: 71
Study 12187208 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month leuprolide acetate (22.5 mg)
Number of subjects: 71
Study 10442361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin and UFT/oral calcium folinate
Number of subjects: 0
Study 10442361 — intervention group
Group type: COMPARATOR
Intervention: UFT/oral calcium folinate
Number of subjects: 0
Study 10442361 — intervention group
Group type: COMPARATOR
Intervention: Oxaliplatin
Number of subjects: 0
Study 7587986 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (Proscar ‐ MSD)
Number of subjects: 0
Study 2132171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (0.1 mg/min for 24 h)
Number of subjects: 43
Study 2132171 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 43
Study 786666 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZ) 1.5 ‐ 2.0 mg/kg/day
Number of subjects: 30
Study 786666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 786666 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZ)
Number of subjects: 30
Study 31034342 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-knee compression garments
Number of subjects: 41
Study 31034342 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression garments)
Number of subjects: 41
Study 29037178 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone website
Number of subjects: 145
Study 29037178 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 145
Study 25175277 — intervention group
Group type: EXPERIMENTAL
Intervention: High verbal patient-centeredness
Number of subjects: 192
Study 25175277 — intervention group
Group type: COMPARATOR
Intervention: Low verbal patient-centeredness
Number of subjects: 192
Study 22820210 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cooling
Number of subjects: 11
Study 22165364 — intervention group
Group type: EXPERIMENTAL
Intervention: Levitan scope (Phase 1)
Number of subjects: 324
Study 22165364 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils scope (Phase 1)
Number of subjects: 324
Study 22165364 — intervention group
Group type: COMPARATOR
Intervention: Levitan scope (Phase 2)
Number of subjects: 324
Study 22165364 — intervention group
Group type: COMPARATOR
Intervention: Bonfils scope (Phase 2)
Number of subjects: 324
Study 22165364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scopes
Number of subjects: 324
Study 19083502 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Ultra
Number of subjects: 292
Study 19083502 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Ultra Plus
Number of subjects: 292
Study 19083502 — intervention group
Group type: COMPARATOR
Intervention: Zyplast collagen
Number of subjects: 292
Study 16562817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean pork (150 g per day)
Number of subjects: 44
Study 16562817 — intervention group
Group type: COMPARATOR
Intervention: Veal (150 g per day)
Number of subjects: 44
Study 12679825 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented with yoghurt cultures and L. casei DN‐114001 for 3 weeks
Number of subjects: 180
Study 12679825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 180
Study 10980510 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-kg small batch (I)
Number of subjects: 0
Study 10980510 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-kg large batch (II)
Number of subjects: 0
Study 10980510 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kg large batch with high shear granulation and microwave drying (IV)
Number of subjects: 0
Study 10980510 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-kg small batch with fluid bed granulation and drying (III)
Number of subjects: 0
Study 10980510 — intervention group
Group type: EXPERIMENTAL
Intervention: multiparticulate capsule (V)
Number of subjects: 0
Study 8741022 — intervention group
Group type: EXPERIMENTAL
Intervention: brofaromine
Number of subjects: 419
Study 8741022 — intervention group
Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 419
Study 8741022 — intervention group
Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale
Number of subjects: 419
Study 8741022 — intervention group
Group type: COMPARATOR
Intervention: von Zerssen Adjective Mood Scale
Number of subjects: 419
Study 1426117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal treadmill movement at frequencies of 0.5, 0.33, and 0.25 Hz with a constant amplitude of +/- 12 cm.
Number of subjects: 3
Study 1426117 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation to a new sinusoidal frequency occurred within 4 cycles following a change in sinus frequency.
Number of subjects: 3
Study 1426117 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural adjustments during treadmill movement.
Number of subjects: 3
Study 4096759 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 19
Study 4096759 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated infants)
Number of subjects: 19
Study 29528443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with 20 to 40 Gy of low-energy photons
Number of subjects: 15
Study 30055579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Baby Triple P
Number of subjects: 0
Study 30055579 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study 26705972 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 0
Study 26705972 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 0
Study 24760645 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 60
Study 23216787 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based education sessions
Number of subjects: 0
Study 23216787 — intervention group
Group type: COMPARATOR
Intervention: Late intervention group (control)
Number of subjects: 0
Study 21066905 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion plus cognitive-behavioral skills building (CBSB)
Number of subjects: 268
Study 21066905 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion without CBSB
Number of subjects: 268
Study 21066905 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion plus CBSB
Number of subjects: 268
Study 16842480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide plus metformin
Number of subjects: 262
Study 16842480 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide plus metformin
Number of subjects: 262
Study 12927012 — intervention group
Group type: EXPERIMENTAL
Intervention: Active high-frequency (20-Hz) rTMS of left dorsolateral prefrontal cortex
Number of subjects: 14
Study 12927012 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 14
Study 10968597 — intervention group
Group type: EXPERIMENTAL
Intervention: Methergine
Number of subjects: 80
Study 10968597 — intervention group
Group type: COMPARATOR
Intervention: No Methergine (Control)
Number of subjects: 80
Study 9315418 — intervention group
Group type: EXPERIMENTAL
Intervention: Allendale-N9 film containing 100 mg N-9
Number of subjects: 10
Study 9315418 — intervention group
Group type: EXPERIMENTAL
Intervention: Allendale-N9 film containing 130 mg N-9
Number of subjects: 10
Study 9315418 — intervention group
Group type: EXPERIMENTAL
Intervention: VCF containing 70 mg N-9
Number of subjects: 10
Study 9315418 — intervention group
Group type: COMPARATOR
Intervention: Baseline cycles (no film used)
Number of subjects: 10
Study 9315418 — intervention group
Group type: EXPERIMENTAL
Intervention: All test cycles (Allendale-N9 and VCF)
Number of subjects: 10
Study 9315418 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 10
Study 1587069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem
Number of subjects: 17
Study 1587069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2418670 — intervention group
Group type: EXPERIMENTAL
Intervention: All-paced (AP) group
Number of subjects: 15
Study 2418670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensed-paced (SP) group
Number of subjects: 15
Study 30165595 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) 3 d/wk for 12 weeks
Number of subjects: 70
Study 30165595 — intervention group
Group type: COMPARATOR
Intervention: Home-based flexibility (FLEX) 3 d/wk for 12 weeks
Number of subjects: 70